Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25)
Marc Raaijmakers, Hartmut Döhner, Dimitri A Breems, John C. Byrd et autres
0 citationsTransplantation and Cellular Therapy